AIMM Therapeutics and Cosmo Pharmaceuticals to Develop Oral Antibodies for Gastrointestinal Diseases - - BioPharm International

ADVERTISEMENT

AIMM Therapeutics and Cosmo Pharmaceuticals to Develop Oral Antibodies for Gastrointestinal Diseases


Pharmaceutical Technology Europe

AIMM Therapeutics and Cosmo Pharmaceuticals have entered into a strategic partnership to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma. AIMM Therapeutics will generate novel human monoclonal antibodies, which will then be formulated by Cosmo Pharmaceuticals into an extended release formulation using its proprietary MMX technology. The financial details of the agreement were not disclosed.

In a press statement, Jan de Vries, CEO of AIMM Therapeutics, said, “The strong preclinical in vivo data generated by Cosmo using its MMX technology show the tremendous potential of oral antibody delivery for gastrointestinal diseases. We expect that the combination of Cosmo’s MMX technology with AIMM’s antibodies will allow us to build a unique portfolio of products with a compelling competitive advantage in gastrointestinal disease.”

Mauro Ajani, chairman and CEO of Cosmo Pharmaceuticals, said, “Access to AIMM’s proprietary high quality antibodies through our partnership will enable us to rapidly advance the oral delivery of diagnostic and therapeutic antibodies into clinical studies.”

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: Pharmaceutical Technology Europe,
Click here